Hilma J. Van Der Horst

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCL.

Cytoskeletal dynamics and mitochondrial rearrangements drive cell fate upon antibody-induced complement activation in DLBCL.

Journal: Blood cancer journal

Published: February 16, 2025

Enhancing Fc-mediated effector functions of monoclonal antibodies: The example of HexaBodies.

Enhancing Fc-mediated effector functions of monoclonal antibodies: The example of HexaBodies.

Journal: Immunological reviews

Published: September 14, 2024

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant.

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant.

Journal: HemaSphere

Published: December 14, 2020

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.

Journal: Blood advances

Published: November 02, 2020

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies.

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies.

Journal: Cancers

Published: September 21, 2020

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.

Journal: Blood cancer journal

Published: August 19, 2020

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies.

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies.

Journal: HemaSphere

Published: August 03, 2020

DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.

DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.

Journal: Blood cancer journal

Published: November 05, 2019

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.

Journal: Haematologica

Published: May 25, 2019

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Journal: Haematologica

Published: October 02, 2018

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: April 12, 2016

Dietary interventions that reduce mTOR activity rescue autistic-like behavioral deficits in mice.

Dietary interventions that reduce mTOR activity rescue autistic-like behavioral deficits in mice.

Journal: Brain, behavior, and immunity

Published: March 20, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026